Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
A phase 3 trial of Pirtobrutinib, Ibrutinib, Acalabrutinib and Zanubrutinib in mantle cell lymphoma, run by Loxo Oncology, Inc., active and no longer recruiting.
Overview
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) is a phase 3 interventional study registered as NCT04662255 by Loxo Oncology, Inc., with 500 participants enrolled, started 2021-04-08 and due to reach its primary completion in 2027-01. Interventions recorded: Pirtobrutinib, Ibrutinib, Acalabrutinib and Zanubrutinib.
Similar pages
not linked directly; found by shared links- TrialA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Pirtobrutinib, Ibrutinib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shares Pirtobrutinib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Shares Acalabrutinib, Ibrutinib and the tag pipeline.
- TrialA Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Shares Pirtobrutinib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Pirtobrutinib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Shares Zanubrutinib, Acalabrutinib and the tag pipeline.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Acalabrutinib, Mantle cell lymphoma and the tag pipeline.
- TrialA Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Shares Zanubrutinib and the tag pipeline.